The Myth of the “Perfect” Embryo
Research shows that PGT-A does not improve pregnancy or live birth rates — especially when counting all patients from the start of treatment (intention-to-treat).
What Are the Limitations?
PGT-A does not lead to better pregnancy or birth rates when all patients are included from the start of treatment.
Inaccurate readings may occur due to mosaicism or DNA testing errors — these can affect up to 25% of results.
Embryos labeled “unsuitable” (e.g., mosaic) have resulted in healthy babies — meaning some may have been discarded unnecessarily.
The test is costly, emotionally exhausting, and often presented as “essential” despite limited evidence of benefit.
Key Takeaways
- PGT-A may not improve outcomes for many patients.
- Small sampling can lead to significant misinterpretation.
- Many “abnormal” embryos may still result in live births.
- Emotional & financial costs can outweigh benefits.
- Paulson, R. J. (2023). Preimplantation genetic testing: The great divide. Fertility and Sterility, 120(3), 408–409.
- Kawwass, J. F., et al. (2024). IVF add-ons and their effectiveness: A systematic review and meta-analysis. Human Reproduction, 39(2), 215–227.
- Gleicher, N., Barad, D. H. (2019). Preimplantation genetic testing for aneuploidy (PGT-A): Finally revealed. ResearchGate Preprint.
This material is for informational purposes only — always consult your doctor before making any decisions.